On March 28, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) ( Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) ) announced the 2021 annual report Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) said that the increase in performance was mainly due to the increase in sales of the company’s eye drops, cephalosporin and other products, as well as the merger of the annual diagnosis and treatment service revenue of Taizhou Hospital of 163 million yuan.
According to the announcement, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) 2021 achieved an operating revenue of 630 million yuan, an increase of 75.8% year-on-year; The net profit attributable to the shareholders of the listed company was 356561 million yuan, and the deducted non net profit attributable to the shareholders of the listed company was 310687 million yuan, which turned losses into profits. Among them, the company’s medical service sector and Taizhou hospital operated stably, contributing a profit of 36.223 million yuan during the reporting period; In the pharmaceutical manufacturing sector, the operating income of eye drops, cephalosporins and other products increased, and the R & D expenses increased significantly during the reporting period.
It is worth mentioning that in 2021, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) R & D expenditure was 1022137 million yuan, a year-on-year increase of 267.66%, accounting for 16.23% of operating revenue. According to the annual report, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) takes ophthalmic drugs as the main line of research and development, and researches and develops pharmaceutical products with independent intellectual property rights. Over the years, the company has always adhered to the R & D mode of combining independent R & D with industry university research cooperation. It has Zhejiang provincial enterprise research institute, which is responsible for the company’s new drug R & D and foreign R & D cooperation.
It is understood that Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) since the change of controlling shareholder in 2020, it has completed the merger of Taizhou hospital and the stripping of Jianshen pharmaceutical industry. At present, its “medicine + medicine” two wheel drive pattern has taken shape.
In the eye medicine sector, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) grasp the development opportunity of the steady growth of eye medicine demand, accelerate the marketing reform, actively explore new sales channels and create a new operation mode; At the same time, increase R & D investment and constantly optimize and enrich the structure of ophthalmic products. In the general medicine sector, the company will participate in the centralized procurement of national drugs and improve product sales. In the medical service sector, Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) continuously improve the quality of medical services and establish a standardized operation system; At the same time, we will promote the construction of phase II project of Taizhou hospital, build key disciplines and move forward to the goal of leading regional private women’s and children’s hospitals.
Zhejiang Shapuaisi Pharmaceutical Co.Ltd(603168) said that 2022 is a key year for the company’s high-quality development. The company will closely grasp the new opportunities brought by the golden stage of pharmaceutical development, strengthen the deep integration of medicine and medicine, and realize the two wheel drive of drug production and medical services.
